ID30485A - Kombinasi obat yang terdiri dari ( e ) 7 [ 4 ( 4 fluorofenil ) 6 isopropil 2 [ metil (metilsulfonil) - amino ] pirimidin 5 il ] (3r,5s) 3,5 dihidroksihept-6- asam enoik dan suatu penghambat, bahat penginduksi atau bahan dari p450 isoenzim 3a4 - Google Patents

Kombinasi obat yang terdiri dari ( e ) 7 [ 4 ( 4 fluorofenil ) 6 isopropil 2 [ metil (metilsulfonil) - amino ] pirimidin 5 il ] (3r,5s) 3,5 dihidroksihept-6- asam enoik dan suatu penghambat, bahat penginduksi atau bahan dari p450 isoenzim 3a4

Info

Publication number
ID30485A
ID30485A IDW00200101892A ID20011892A ID30485A ID 30485 A ID30485 A ID 30485A ID W00200101892 A IDW00200101892 A ID W00200101892A ID 20011892 A ID20011892 A ID 20011892A ID 30485 A ID30485 A ID 30485A
Authority
ID
Indonesia
Prior art keywords
pyrimidine
amino
metylsulfonyl
methodsulfonyl
isoenzim
Prior art date
Application number
IDW00200101892A
Other languages
English (en)
Indonesian (id)
Inventor
Ali Raza
John Stuart Pears
Howard Gerard Hutchinson
Dennis Schneck
Takahiko Baba
Akira Touchi
Yoshitaka Yamaguchi
Original Assignee
Astrazeneca Ab
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27269637&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ID30485(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9902593.4A external-priority patent/GB9902593D0/en
Priority claimed from GBGB9921064.3A external-priority patent/GB9921064D0/en
Priority claimed from GBGB9921063.5A external-priority patent/GB9921063D0/en
Application filed by Astrazeneca Ab, Shionogi & Co filed Critical Astrazeneca Ab
Publication of ID30485A publication Critical patent/ID30485A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IDW00200101892A 1999-02-06 2000-02-01 Kombinasi obat yang terdiri dari ( e ) 7 [ 4 ( 4 fluorofenil ) 6 isopropil 2 [ metil (metilsulfonil) - amino ] pirimidin 5 il ] (3r,5s) 3,5 dihidroksihept-6- asam enoik dan suatu penghambat, bahat penginduksi atau bahan dari p450 isoenzim 3a4 ID30485A (id)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9902593.4A GB9902593D0 (en) 1999-02-06 1999-02-06 Drug combinations
GBGB9921064.3A GB9921064D0 (en) 1999-09-08 1999-09-08 Drug combination
GBGB9921063.5A GB9921063D0 (en) 1999-09-08 1999-09-08 Therapy

Publications (1)

Publication Number Publication Date
ID30485A true ID30485A (id) 2001-12-13

Family

ID=27269637

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW00200101892A ID30485A (id) 1999-02-06 2000-02-01 Kombinasi obat yang terdiri dari ( e ) 7 [ 4 ( 4 fluorofenil ) 6 isopropil 2 [ metil (metilsulfonil) - amino ] pirimidin 5 il ] (3r,5s) 3,5 dihidroksihept-6- asam enoik dan suatu penghambat, bahat penginduksi atau bahan dari p450 isoenzim 3a4

Country Status (28)

Country Link
US (3) US6982157B1 (enExample)
EP (1) EP1185274B1 (enExample)
JP (2) JP2002536331A (enExample)
KR (2) KR20010101790A (enExample)
CN (1) CN1165310C (enExample)
AR (1) AR029333A1 (enExample)
AT (1) ATE282415T1 (enExample)
AU (1) AU767304B2 (enExample)
BR (1) BR0007999A (enExample)
CA (1) CA2358632C (enExample)
CZ (1) CZ301296B6 (enExample)
DE (1) DE60015965T2 (enExample)
EE (1) EE04929B1 (enExample)
EG (1) EG23858A (enExample)
ES (1) ES2232418T3 (enExample)
GB (1) GB0000710D0 (enExample)
ID (1) ID30485A (enExample)
IL (1) IL144715A0 (enExample)
IS (1) IS2337B (enExample)
MX (1) MXPA01007905A (enExample)
MY (1) MY130606A (enExample)
NO (1) NO320745B1 (enExample)
NZ (1) NZ512982A (enExample)
PL (1) PL198034B1 (enExample)
PT (1) PT1185274E (enExample)
TR (1) TR200102228T2 (enExample)
TW (1) TWI282738B (enExample)
WO (1) WO2000045817A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
DE19944803A1 (de) * 1999-09-20 2001-03-29 Bayer Ag Kombination von Dihydropyridinverbindungen und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
GB0003305D0 (en) * 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
KR20070120617A (ko) 2001-01-26 2007-12-24 쉐링 코포레이션 치환된 아제티딘온 화합물을 포함하는 약제학적 조성물
IL156445A0 (en) 2001-01-26 2004-01-04 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
EP1429756B1 (en) 2001-09-21 2006-11-22 Schering Corporation Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
CA2504916A1 (en) 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
WO2004081004A1 (en) 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
WO2004081002A1 (en) 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
DE602004018617D1 (de) 2003-03-07 2009-02-05 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
US9173847B2 (en) 2003-10-10 2015-11-03 Veloxis Pharmaceuticals A/S Tablet comprising a fibrate
KR20060085686A (ko) 2003-10-10 2006-07-27 라이프사이클 파마 에이/에스 피브레이트를 포함하는 고형 제제
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
KR20070038553A (ko) 2004-08-06 2007-04-10 트렌스폼 파마수티컬스 인코퍼레이티드 신규한 스타틴 약제학적 조성물 및 관련된 치료방법
WO2007005941A2 (en) 2005-07-05 2007-01-11 President And Fellows Of Harvard College Liver targeted conjugates
WO2007071357A2 (en) 2005-12-20 2007-06-28 Lek Pharmaceuticals D.D. Pharmaceutical composition comprising (e) -7- [4- (4-fluorophenyl) -6-isopropyl-2- [methyl (methylsulfonyl) amino] pyrimidin-5 -yl- (3r, 5s) -3, 5-dihydr0xyhept-6-en0ic acid
US20080109252A1 (en) * 2006-11-08 2008-05-08 Lafountain Andrea Predicting patient compliance with medical treatment
US20120130202A1 (en) * 2010-11-24 2012-05-24 Fujitsu Limited Diagnosis and Monitoring of Musculoskeletal Pathologies
CN112955965B (zh) * 2018-06-14 2024-04-09 阿斯利康(英国)有限公司 使用二氢吡啶类钙通道阻断剂医药组合物降低血压的方法
LT4115879T (lt) 2019-07-31 2026-01-26 Intas Pharmaceuticals Ltd. Farmacinė kompozicija, apimanti hmg-coa reduktazės inhibitorius ir fenofibratą
WO2024223797A1 (en) 2023-04-28 2024-10-31 Institut National de la Santé et de la Recherche Médicale Use of cyp3a4 inhibitors for the treatment of hepatitis d virus (hdv) infections

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2627696B1 (fr) * 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
EP0521417B1 (de) * 1991-07-02 1994-11-23 Joh. A. Benckiser GmbH Zusammenfaltbare Vorratsflasche
JP3852621B2 (ja) * 1992-01-21 2006-12-06 あすか製薬株式会社 血管内皮細胞機能改善剤
FR2730231B1 (fr) * 1995-02-02 1997-04-04 Fournier Sca Lab Association de fenofibrate et de vitamine e, utilisation en therapeutique
KR20010031501A (ko) * 1997-10-31 2001-04-16 추후제출 5-알파 환원효소 활성을 조절하는 방법 및 조성물

Also Published As

Publication number Publication date
MY130606A (en) 2007-07-31
US20060040969A1 (en) 2006-02-23
EP1185274B1 (en) 2004-11-17
KR20010101790A (ko) 2001-11-14
AU2121800A (en) 2000-08-25
DE60015965D1 (de) 2004-12-23
CZ301296B6 (cs) 2010-01-06
DE60015965T2 (de) 2006-01-05
BR0007999A (pt) 2001-11-06
ATE282415T1 (de) 2004-12-15
CA2358632A1 (en) 2000-08-10
AR029333A1 (es) 2003-06-25
NO20013811L (no) 2001-10-02
PL198034B1 (pl) 2008-05-30
HK1041817A1 (en) 2002-07-26
GB0000710D0 (en) 2000-03-08
PL364780A1 (en) 2004-12-13
US20090042911A1 (en) 2009-02-12
CN1338936A (zh) 2002-03-06
CN1165310C (zh) 2004-09-08
JP2007277267A (ja) 2007-10-25
TR200102228T2 (tr) 2002-03-21
TWI282738B (en) 2007-06-21
NO20013811D0 (no) 2001-08-03
MXPA01007905A (es) 2003-06-04
AU767304B2 (en) 2003-11-06
NZ512982A (en) 2003-08-29
ES2232418T3 (es) 2005-06-01
NO320745B1 (no) 2006-01-23
IS2337B (is) 2008-02-15
PT1185274E (pt) 2005-03-31
EP1185274A1 (en) 2002-03-13
IS6009A (is) 2001-07-17
EG23858A (en) 2007-11-18
WO2000045817A1 (en) 2000-08-10
CZ20012844A3 (cs) 2001-11-14
JP2002536331A (ja) 2002-10-29
CA2358632C (en) 2008-10-28
KR20060117381A (ko) 2006-11-16
EE04929B1 (et) 2007-12-17
IL144715A0 (en) 2002-06-30
US6982157B1 (en) 2006-01-03
EE200100406A (et) 2002-10-15

Similar Documents

Publication Publication Date Title
FR2811552B1 (fr) Composition notamment cosmetique ou pharmaceutique se presentant sous forme solide
DE59812907D1 (de) Substituierte Isochinolin-3-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
HUP0004310A3 (en) Cyclic amino acids, and derivatives thereof and pharmaceutical compositions comprising the said compounds as active agents
AU1979501A (en) Optically active materials
AU3813499A (en) The use of dihydropyrimidines as medicaments, and novel substances
IL163552A (en) Conjugates of biologically active compounds, uses thereof and pharmaceutical compositions comprising the same
AU3157801A (en) Beta-amino acid compounds as integrin antagonists
BR9807814B1 (pt) composto de pirazina, composiÇço farmacÊutica, uso de um composto, e, processo para a preparaÇço de um composto.
AU2003252299A1 (en) Novel physiologically active substance
PT1169460E (pt) Preparacao de moleculas biologicamente activas.
AU5210798A (en) Nucleic acid construct for expressing active substances which can be activated by proteases, and preparation and use
BR0014465B1 (pt) 1,1'-bifenil-2-carbonamidas 2'-substituÍdas, preparado farmacÊutico e aplicaÇÕes dos referidos compostos.
DE69937573D1 (de) Extrazelluläres, neues rage-bindendes protein (en-rage) und dessen verwendungen
AU2759800A (en) Processes and intermediates for the preparation of 1,3-oxazin-6-ones and uracils
AU2002238855A1 (en) N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same
DE50305374D1 (de) Neue prodrugs von 1-methyl-2-(4-amidinophenylaminomethyl)-benzimidazol-5-yl-carbonsäure-(n -2-pyridil-n-2-hydroxycarbonylethyl)-amid, ihre herstellung und ihre verwendung als arzneimittel
ZA200201521B (en) Alkoxy substituted benzimidazole compounds, pharmaceutical preparation containing the same, and methods of using the same.
AU5404800A (en) Process for the preparation of optically active n-acyl derivatives of methyl n-(2,6-dimethylphenyl)-d-alaninate
HUP0203275A3 (en) 1-cyclic amino-alkylcyclohexane compounds, pharmaceutical compositions thereof, and their use as anticonvulsants
CA2379314A1 (en) Tablet for sucking, containing ambroxol
EP1369479A4 (en) Novel cell adhesion molecule specific to activated leukocyte
DZ3163A1 (fr) Nouvelle substance pharmaceutique.
AU2001274171A1 (en) Aminothiolester compounds, pharmaceutical and cosmetic compositions containing same and uses thereof
IL164901A0 (en) Optically active beta-aminoketones, optically active 1,3-aminoalcohols and processes for preparing them
AU1411200A (en) Novel physiologically active substance, process for producing the same and utilization thereof